Protalix Biotherapeutics, Inc.

Biotechnology • Healthcare • Hackensack, NJ, United States • PLX (ASE)

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. It operates in the United States, Australia, Canada, Israel, Brazil, Russia, and Turkey. The company is headquartered in Hackensack. New Jersey.

Wikipedia

Stock Performance (90 Days)

Data through Dec 24, 2025

Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Protalix BioTherapeutics Reports Second Quarter 2025 Financial and Business Results - PR Newswire

PR Newswire • Aug 14

Protalix BioTherapeutics, Inc. (PLX) Gains Investor Confidence With Major Stake Increase - Yahoo Finance

Yahoo Finance • Sep 29

Protalix BioTherapeutics Stock Tumbled 28% Today: Why The Latest CHMP Opinion Is Sparking Concerns Among Investors? - Stocktwits

Stocktwits • Oct 17

Bashan Dror, Protalix BioTherapeutics CEO, buys $101k in shares By Investing.com - Investing.com Nigeria

Investing.com Nigeria • Dec 23

Protalix BioTherapeutics (NYSE:PLX) CEO Buys $101,360.00 in Stock - MarketBeat

MarketBeat • Dec 23

Other Biotechnology Companies

Vertex Pharmaceuticals Inc. / MA

$118.68B market cap

Regeneron Pharmaceuticals, Inc.

$82.72B market cap

Alnylam Pharmaceuticals, Inc.

Frequently Asked Questions

Has Protalix BioTherapeutics, Inc. had layoffs?

No layoff events have been recorded for Protalix BioTherapeutics, Inc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.

How many employees does Protalix BioTherapeutics, Inc. have?

Protalix BioTherapeutics, Inc. has approximately 213 employees.

What industry is Protalix BioTherapeutics, Inc. in?

Protalix BioTherapeutics, Inc. operates in the Biotechnology industry, within the Healthcare sector.

Is Protalix BioTherapeutics, Inc. a publicly traded company?

Yes, Protalix BioTherapeutics, Inc. is publicly traded under the ticker symbol PLX on the ASE. The company has a market capitalization of approximately $0.14 billion.

Where is Protalix BioTherapeutics, Inc. headquartered?

Protalix BioTherapeutics, Inc. is headquartered in Hackensack, NJ, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.